RT Journal Article
SR Electronic
T1 Expansion, persistence and efficacy of donor memory-like NK cells for the treatment of post-transplant relapse
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.24.21262547
DO 10.1101/2021.08.24.21262547
A1 Shapiro, Roman M.
A1 Birch, Grace
A1 Vergara, Juliana
A1 Hu, Guangan
A1 Nikiforow, Sarah
A1 Baginska, Joanna
A1 Ali, Alaa
A1 Tarannum, Mubin
A1 Rambaldi, Benedetta
A1 Arihara, Yohei
A1 Reynolds, Carol
A1 Halpern, Max
A1 Rodig, Scott
A1 Cullen, Nicole
A1 Lane, Andrew A.
A1 Lindsley, R. Coleman
A1 Cutler, Corey S.
A1 Antin, Joseph H.
A1 Ho, Vincent T.
A1 Koreth, John
A1 Gooptu, Mahasweta
A1 Kim, Haesook T.
A1 Malmberg, Karl-Johan
A1 Wu, Catherine J.
A1 Chen, Jianzhu
A1 Soiffer, Robert J.
A1 Ritz, Jerome
A1 Romee, Rizwan
YR 2021
UL http://medrxiv.org/content/early/2021/08/30/2021.08.24.21262547.abstract
AB Background Responses to conventional donor lymphocyte infusion (DLI) for post-allogeneic hematopoietic cell transplantation (HCT) relapse are typically poor. Natural killer (NK) cell-based therapy is a promising modality to treat post-HCT relapse.Methods We initiated this ongoing phase 1 trial of adoptively transferred cytokine induced memory-like (CIML) NK cells in patients with myeloid malignancies relapsed after haploidentical HCT. All patients received a donor-derived NK cell dose of 5-10 × million cells/kg after lymphodepleting chemotherapy, followed by systemic IL-2 for 7 doses. High resolution profiling with mass cytometry and single cell RNA sequencing characterized the expanding and persistent NK cells subpopulations in a longitudinal manner after infusion. In vitro functional studies of infused CIML NK cells were complemented with in vivo evaluation of NK trafficking to disease sites using multiparameter immunofluorescence.Results In the first 5 patients on the trial, infusion of CIML NK cells led to a rapid 10 to 50-fold in vivo expansion that was sustained over months. The infusion was well-tolerated, with fever and pancytopenia as the most common adverse events. Responses were attained in 4 of 5 patients at day +28. Immunophenotypic and transcriptional profiling revealed a dynamic evolution of the activated CIML NK cell phenotype, superimposed on the natural variation in donor NK cell repertoires. AML relapse after initial response to CIML NK cell therapy was associated with low transcript expression of CD2 ligands, including CD48/SLAMF2 and CD58/LFA3.Conclusion Given their rapid expansion and long-term persistence in an immune compatible environment, CIML NK cells serve as a promising platform for the treatment of post-transplant relapse of myeloid disease. Further characterization of their unique in vivo biology and interaction with both T-cells and tumor targets will lead to the development of novel cell-based immunotherapies.Competing Interest StatementSN is on the advisory board of Kite, Novartis, and Nkarta. BR receives research funding from Equillium. SR receives research funding from Bristol-Myers-Squibb and KITE/Gilead and is on the scientific advisory board for Immunitas Pharmaceuticals. AAL consults for Qiagen and receives research funding from AbbVie and Stemline Therapeutics. CSC consults or is on the advisory board of Incyte, Kadmon, Jazz, Medsenic, Generon, and Mesoblast. JK is on the advisory board of Therakos and Cugene, and receives research funding from Miltenyi, BMS, and Regeneron. CJW is an equity holder in BioNTech and receives funding from Pharmacyclics. KJM is a consultant at Fate Therapeutics and Vycellix and receive research funding from Fate Therapeutics and Merck. RJS consults or is on the advisory board of Kiadis, Juno Therapeutics, Gilead, Jasper, Jazz Pharmaceuticals, Precision Biosciences, Rheos Therapeutics, Takeda, and NMDP Be the Match. JR receives funding from Amgen, Equillium, and Kite Pharma. RR receives funding from CRISPR Therapeutics and is on the advisory board of Glycostem.Clinical TrialNCT04024761Funding StatementThis work was supported by grants awarded to Dr. Rizwan Romee, including the Dunkin Donuts Breakthrough grant, the NIH/National Cancer Institute (NCI) R21 CA245413 grant, and the Leukemia and Lymphoma Society Scholar award. Additional philanthropic support was provided by the Michelle D. and Douglas W. Bell Fund for Engineered Adoptive Immunotherapy Ted and Eileen Pasquarello Research Fund. The funding sources had no role in the design of this study, its execution, analyses, interpretation of the data, or decision to submit the results. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All studies described in this manuscript were approved by the IRB at the Dana-Farber Cancer Institute under protocol 19-265.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified correlative study data used for all analyses and to generate the figures is available upon request with the permission of the corresponding author.